Systemic cytotoxic and biological therapies of colorectal liver metastases: Expert consensus statement

HPB

Volumn 15, Issue 2, 2013, Pages 106-115

  Schwarz, Roderich E ^a   Berlin, Jordan D ^b   Lenz, Heinz J ^c   Nordlinger, Bernard ^d,e   Rubbia Brandt, Laura ^f   Choti, Michael A ^g  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HÔPITAL AMBROISE PARÉ   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FATTY LIVER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER INJURY; LIVER METASTASIS; LIVER RESECTION; LIVER VENOOCCLUSIVE DISEASE; NEUROPATHY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84872191543     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2012.00558.x     Document Type: Article

References (89)

1. Leonard GD, Brenner B, Kemeny NE,. (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23: 2038-2048. (Pubitemid 46211384)
2. Scheele J, Stang R, Altendorf-Hofmann A, Paul M,. (1995) Resection of colorectal liver metastases. World J Surg 19: 59-71.
3. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH,. (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230: 309-318; discussion 318-321.
4. Langer B, Bleiberg H, Labianca R, Shepherd L, Nitti D, Marsoni S, et al. (2002) Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 21 (149a): Abstract 592.
5. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24: 4976-4982. (Pubitemid 46631399)
6. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al. (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A pooled analysis of two randomized trials. J Clin Oncol 26: 4906-4911.
7. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, et al. (2009) A randomized phase III study comparing adjuvant 5-fluorouracil/ folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20: 1964-1970.
8. Reddy SK, Zorzi D, Lum YW, Barbas AS, Pawlik TM, Ribero D, et al. (2009) Timing of multimodality therapy for resectable synchronous colorectal liver metastases: A retrospective multi-institutional analysis. Ann Surg Oncol 16: 1809-1819.
9. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241: 715-722; discussion 722-724.
10. Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, et al. (2011) Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Oncology 81: 175-183.
11. Lorenz M, Muller HH, Schramm H, Gassel HJ, Rau HG, Ridwelski K, et al. (1998) Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228: 756-762. (Pubitemid 30191686)
12. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al. (1999) Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341: 2039-2048. (Pubitemid 30035952)
13. Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, et al. (2002) Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 20: 1499-1505. (Pubitemid 34260528)
14. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al. (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18: 299-304. (Pubitemid 46323097)
15. Blazer DG, 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. (2008) Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26: 5344-5351.
16. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 371: 1007-1016. (Pubitemid 351392040)
17. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243: 1-7. (Pubitemid 43054046)
18. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. (2010) Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17: 2870-2876.
19. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, et al. (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206: 96-106. (Pubitemid 350267242)
20. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al. (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110: 2761-2767. (Pubitemid 350250347)
21. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, et al. (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101: 1033-1038.
22. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22: 229-237. (Pubitemid 41095086)
23. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866-4875. (Pubitemid 46223991)
24. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069. (Pubitemid 46606353)
25. Grothey A, Sargent D, Goldberg RM, Schmoll HJ,. (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214. (Pubitemid 41079833)
26. Kelly H, Goldberg RM,. (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23: 4553-4560. (Pubitemid 46196586)
27. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779-4786. (Pubitemid 350086481)
28. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. (2006) OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24: 394-400. (Pubitemid 46630458)
29. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, et al. (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27: 5727-5733.
30. Labianca R, Floriani I, Cortesi E, Tract IGftSoD. (2006) Can alternating versus continuous 'FOLFIRI' in advanced colorectal cancer (ACC): A randomized 'GISCAD' trial. J Clin Oncol 24 (Suppl.): Abstract 3505.
31. Lal K, Norman AR, Ross PJ, Ageli S, Oates J, Massey A, et al. (2003) A phase III, randomized, multicentre, trial of irinotecan until disease progression (PD) versus 8 cycles, in advanced colorectal cancer (CRC) resistant to fluoropyrimidines. Proc Am Soc Clin Oncol 22: Abstr 1017.
32. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370: 143-152. (Pubitemid 47042894)
33. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 370: 135-142. (Pubitemid 47042893)
34. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676. (Pubitemid 46797946)
35. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): A multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94: 798-805.
36. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240: 644-657; discussion 657-658.
37. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH,. (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16: 1311-1319. (Pubitemid 41158476)
38. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26: 2013-2019.
39. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342. (Pubitemid 38702844)
40. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546.
41. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.
42. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019.
43. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65.
44. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544. (Pubitemid 46733080)
45. Fuchs CS, Marshall J, Barrueco J,. (2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26: 689-690. (Pubitemid 351264373)
46. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26: 5326-5334.
47. Cohn A, Bekaii-Saab T, Bendell J,. (2010) Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol 28 (Suppl.): 15s; abstr 3596.
48. Arnold D, Andre T, Bennouna J, Sastre J, Osterlund P, Greil R, et al. (2012) Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup sudy (TML study). J Clin Oncol 30 (Suppl.): Abstr. CRA3503.
49. Jain VK, Hawkes EA, Cunningham D,. (2011) Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer 10: 245-257.
50. Tabernero J, Van Cutsem E, Lakomy R,. Results from VELOUR, a phase 3 study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer. 2011 European Multidisciplinary Congress. 2011: Abstract 6LBA.
51. Gaya A, Tse V,. (2012) A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 38: 484-493.
52. Grothey A, Sobrero A, Siena S,. (2012) Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol 30 (Suppl. 4): Abstr LBA385.
53. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048. (Pubitemid 350106711)
54. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664. (Pubitemid 46797944)
55. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
56. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
57. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345. (Pubitemid 38944402)
58. Adam R, Haller DG, Poston G, Raoul JL, Spano JP, Tabernero J, et al. (2010) Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol 21: 1579-1584.
59. Goere D, Gaujoux S, Deschamp F, Dumont F, Souadka A, Dromain C, et al. (2011) Patients operated on for initially unresectable colorectal liver metastases with missing metastases experience a favorable long-term outcome. Ann Surg 254: 114-118.
60. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-3237. (Pubitemid 47325606)
61. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9: 962-972.
62. Winder T, Lenz HJ,. (2010) Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev 36: 550-556.
63. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK,. (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94: 274-286. (Pubitemid 46423843)
64. Chun YS, Laurent A, Maru D, Vauthey JN,. (2009) Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 10: 278-286.
65. Pascale A, Pais R, Ratziu V,. (2010) An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis 19: 415-423.
66. Brunt EM, Tiniakos DG,. (2010) Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 16: 5286-5296.
67. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM,. (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200: 845-853. (Pubitemid 40744790)
68. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24: 2065-2072. (Pubitemid 46622116)
69. Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, et al. (2009) Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 145: 362-371.
70. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15: 460-466. (Pubitemid 38444550)
71. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. (2010) Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56: 430-439.
72. Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, et al. (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24: 4983-4990. (Pubitemid 46631400)
73. Arotcarena R, Cales V, Berthelemy P, Parent Y, Malet M, Etcharry F, et al. (2006) Severe sinusoidal lesions: A serious and overlooked complication of oxaliplatin-containing chemotherapy? Gastroenterol Clin Biol 30: 1313-1316. (Pubitemid 46031732)
74. Hubert C, Sempoux C, Horsmans Y, Rahier J, Humblet Y, Machiels JP, et al. (2007) Nodular regenerative hyperplasia: A deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int 27: 938-943. (Pubitemid 47261947)
75. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247: 118-124.
76. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, et al. (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35: 515-520.
77. Rubbia-Brandt L,. (2010) Sinusoidal obstruction syndrome. Clin Liver Dis 14: 651-668.
78. Morris-Stiff G, Tan YM, Vauthey JN,. (2008) Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol 34: 609-614. (Pubitemid 351671976)
79. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, et al. (2009) Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8: 225-230.
80. Wicherts DA, de Haas RJ, Sebagh M, Ciacio O, Levi F, Paule B, et al. (2011) Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol 18: 659-669.
81. Tisman G, MacDonald D, Shindell N, Reece E, Patel P, Honda N, et al. (2004) Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 22: 3202-3204.
82. Soubrane O, Brouquet A, Zalinski S, Terris B, Brezault C, Mallet V, et al. (2010) Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 251: 454-460.
83. Ward J, Guthrie JA, Sheridan MB, Boyes S, Smith JT, Wilson D, et al. (2008) Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol 26: 4304-4310.
84. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, et al. (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302: 2338-2344.
85. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, et al. (2010) Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28: 2549-2555.
86. Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M,. (2007) Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 96: 1037-1042. (Pubitemid 46608314)
87. Solis-Herruzo JA, Vidal JV, Colina F, Santalla F, Castellano G,. (1986) Nodular regenerative hyperplasia of the liver associated with the toxic oil syndrome: report of five cases. Hepatology 6: 687-693. (Pubitemid 16038190)
88. Rubbia-Brandt L, Tauzin S, Brezault C, Delucinge-Vivier C, Descombes P, Dousset B, et al. (2011) Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther 10: 687-696.
89. Wicherts DA, de Haas RJ, Sebagh M, Saenz Corrales E, Gorden DL, Levi F, et al. (2011) Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Br J Surg 98: 399-407.